Clinical Trials Browser

OTHER × Neoplasms × durvalumab × Clear all

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT03911557 2025-11-12

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Phase 2 Completed

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT06031233 2025-05-21

MINUTE

Phase 4 Recruiting

Neoplasms

NCT03406650 2025-05-04

SAKK 06/17

Phase 2 Completed

Neoplasms

NCT03094286 2024-06-24

Durvalumab in HIV-1 Patients With Solid Tumors

Phase 2 Completed

20 enrolled 36 charts

Neoplasms

NCT04392505 2024-02-29

DART

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02904954 2023-10-11

Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer

Phase 2 Completed

60 enrolled 12 charts

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT03759496 2022-03-23

Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer

Phase 2 Unknown

Urinary Bladder Neoplasms, Neoplasms